AIM ImmunoTech (NYSE:AIM) Stock Price Down 3.3% – Here’s What Happened

AIM ImmunoTech Inc. (NYSE:AIM)’s share price traded down 3.3% on Friday . The company traded as low as $0.24 and last traded at $0.25. 145,878 shares were traded during mid-day trading, a decline of 43% from the average session volume of 254,026 shares. The stock had previously closed at $0.26.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets cut their price objective on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

AIM ImmunoTech Trading Down 3.3 %

The company has a 50 day moving average of $0.30 and a 200 day moving average of $0.37. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.17 and a current ratio of 1.17. The stock has a market capitalization of $12.89 million, a price-to-earnings ratio of -0.39 and a beta of -0.39.

AIM ImmunoTech (NYSE:AIM) last issued its earnings results on Wednesday, August 14th. The company reported ($0.03) EPS for the quarter. The business had revenue of $0.05 million during the quarter. AIM ImmunoTech had a negative net margin of 13,952.74% and a negative return on equity of 269.04%. On average, research analysts predict that AIM ImmunoTech Inc. will post -0.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC acquired a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).